Non Replicatig Viral Vector | Adeno-based | Gamaleya Research Institute | SARS-CoV-2 | Phase 1 NCT04436471 NCT04437875 |
|
Protein Subunit | Native like Trimeric subunit Spike Protein vaccine | Clover Biopharmaceuticals Inc./GSK/Dynavax | SARS-CoV-2 | Phase 1 NCT04405908 | HIV, REV Influenza |
Protein Subunit | Recombinant spike protein with Advax™ adjuvant | Vaxine Pty Ltd/Medytox | SARS-CoV-2 | Phase 1 NCT04453852 |
|
Protein Subunit | Molecular clamp stabilized Spike protein with MF59 adjuvant | University of Queensland/CSL/Seqirus | SARS-CoV-2 | Phase 1 ACTRN12620000674932p | Nipah, influenza, Ebola, Lassa |
RNA | LNP-nCoVsaRNA | Imperial College London | SARS-CoV-2 | Phase 1 ISRCTN17072692 | EBOV; LASV, MARV, Inf (H7N9), RABV |
RNA | mRNA | Curevac | SARS-CoV-2 | Phase 1 NCT04449276 | RABV, LASV, YFV; MERS, InfA, ZIKV, DENV, NIPV |
RNA | mRNA | People’s Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech. | SARS-CoV-2 | Phase 1 ChiCTR2000034112 |
|
VLP | Plant-derived VLP adjuvanted with GSK or Dynavax adjs. | Medicago Inc. | SARS-CoV-2 | Phase 1 NCT04450004 | Flu, Rotavirus, Norovirus, West Nile virus, Cancer |